Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Francesco Bonella (Dusseldorf, Germany), Francesco Bonella, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus Keller, Martin J. Kohlhäufl, Joachim Müller-Quernheim, Katrin Milger, Antje Prasse. Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP). Eur Respir J 2016; 48: Suppl. 60, 2090

Member's Comments

No comment yet.

Related content which might interest you: Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia Source: International Congress 2017 – Clinical problems in lung diseases Year: 2017 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 246s Year: 2007 Idiopathic pulmonary fibrosis (IPF): the patient journey Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF) Source: Eur Respir J 2007; 30: Suppl. 51, 121s Year: 2007 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013